Navigation Links
Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
Date:12/13/2012

etic disease in which the patient inherits a mutant gene that produces a misfolded form of TTR, which progressively accumulates in tissues, impairing their function.  In patients with transthyretin amyloidosis, both the mutant and normal forms of TTR can build up as fibrils in tissues, including heart, peripheral nerves, and the gastrointestinal tract.  The presence of TTR aggregates interferes with the normal functions of these tissues, and as the TTR protein aggregates enlarge more tissue damage occurs and the disease worsens.  There are two common types of transthyretin amyloidosis, familial amyloid cardiomyopathy, or FAC, which affects more than 40,000 patients worldwide, and FAP, which affects more than 10,000 patients worldwide.  Patients with FAC have TTR build up in the heart muscle and succumb to heart failure five to six years after symptom onset.  Patients with FAP have TTR build up in peripheral nerve tissue leading to the loss of nerve function and wasting.  ISIS-TTRRx is an investigational drug that is designed to inhibit the production of all forms of TTR, and could offer an alternative approach to treat all types of transthyretin-related amyloidosis. 

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, in the United States and Europe following regulatory approval.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MAQUET Cardiovascular Announces U.S. Food and Drug Administration Panel Votes To Reclassify Intra-Aortic Balloon Pumps To A Class II Designation In Certain Indications
2. CVS Caremark Provides Strong Growth Outlook for 2013 and Beyond, Announces 38%Dividend Increase and Outlines Strategic Growth Framework
3. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
4. Mylan Announces Pricing of Senior Notes
5. AAIPharma Announces Promotion Of Dean Shirazi To EVP Of Analytical Laboratories
6. Alere Inc. Announces Hiring of Namal Nawana as Chief Operating Officer
7. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
8. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
9. River Vision Announces Completion of $17 million Series A Financing
10. Winner Medical Announces Closing of Going Private Transaction
11. Alere Inc. Announces Early Results of its Tender Offer and Consent Solicitation for Any and All of its 7.875% Senior Notes due 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)( ... the development of oral drug delivery systems, announces ... to discuss the clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes ... Eastern time. Shareholders and other interested ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3
... 6 month results from long term durability study presented ... Section meeting of the American Urological Association, ... of innovative therapies in women,s health, announced today that,six ... to,evaluate the long term durability of the Renessa(R) treatment ...
... Community Oncology,Alliance (COA), representing community cancer centers ... & Medicaid Services (CMS),reconsider its decision to ... to,vital anemia-fighting drugs. Effective July 30, 2007, ... oncologists, use of,anemia-fighting drugs, referred to as ...
Cached Medicine Technology:New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence 2New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence 3Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions 2
(Date:10/31/2014)... 2014 (HealthDay News) -- Carving pumpkins and trick-or-treating may ... children to emergency rooms in the United States every ... had the fifth highest number of ER visits involving ... data from the National Electronic Injury Surveillance System. ... head, noted the American Academy of Orthopaedic Surgeons and ...
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. ... all public health tactics known to prevent Ebola transmission ... epidemic, a new study reports. Four practices in ... way, immediately isolating new patients, tracing people potentially exposed ... care workers -- can stop the epidemic within six ...
(Date:10/31/2014)... National Institutes of Health will facilitate communication among ... health research, from diagnosis to treatment. The Research ... the National Institute of Mental Health (NIMH), part ... institute,s RDoC initiative. , The aim of ... of research that translates basic science into clinical ...
(Date:10/31/2014)... are clear differences in the brains of people with ... new research indicates. Scientists at Stanford University ... diagnose this baffling condition and shed light on how ... misdiagnosed or labeled as hypochondriacs. Using three ... [chronic fatigue syndrome] patients, brains diverge from those of ...
(Date:10/31/2014)... (HealthDay News) -- A comparison of two of the ... laparoscopic gastric bypass helped patients shed more excess pounds ... of short-term complications and long-term hospitalizations. Gastric-bypass surgery ... so your body does not absorb all the calories ... of Health. Gastric banding is a type of weight-loss ...
Breaking Medicine News(10 mins):Health News:Halloween at the ER Is No Treat 2Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 2Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 3Health News:NIMH creates new unit to support its research domain criteria initiative 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 3Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3
... Mass. -- A subtle mutation affecting the epigenome - a ... lead to an inherited form of mental retardation that affects ... also involves cleft lip or cleft palate, appears to hinge ... offer several potential drug targets. The study, published online ...
... Professor of Public Health and Director of Health Promotion ... evidence that supports relationships seen in adolescents between insulin ... fat and identifies additional potential early markers of insulin ... including fat in muscle cells, blood pressure, physical activity, ...
... HealthDay Reporter , FRIDAY, July 9 (HealthDay News) -- One ... of Avandia, new doubts surfaced Friday on a key trial ... A medical reviewer for the U.S. Food and Drug ... that drugmaker GlaxoSmithKline,s "mishandling" of trial results may have ...
... the 52nd meeting of the American Association of Physicists ... 22, 2010 in Philadelphia, PA, thousands of scientists and ... developments in medical imaging and radiation therapy, examine new ... ethical and regulatory issues that face the field today. ...
... Researchers at Brown University have found that the length of ... doubled during the last 10 years. The study, which will ... the American Geriatrics Society , evaluated hospice use in U.S. ... treatment time has increased from 46 to 93 days. The ...
... HCG True Diet offers ... ... photos and revamped the before and after section of the website. The pictures can be ... taken of a patient before they start the HCG True Diet and after they finish the ...
Cached Medicine News:Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 2Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 3Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 2Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 3Health News:FDA Reviewer Questions Results of Key Avandia Trial 2Health News:FDA Reviewer Questions Results of Key Avandia Trial 3Health News:FDA Reviewer Questions Results of Key Avandia Trial 4Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 2Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 3Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 4Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 5Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 6Health News:Study: Medicare policy may account for growing length of hospice stays in nursing homes 2Health News:See New HCG Diet Before and After Photos 2
MONOJECT SUPRA/HONE Blood Collection Needles - Thin Wall...
VACUETTE PaediatricMulti-Sample Needle...
... Blood Collection Needles are preominantly used for ... single-use. The colour of the needle protective ... needle gauges. For example, yellow symbolises the ... 21 G (0.80 mm) and black 22 ...
This is adapted to microplate or card....
Medicine Products: